Last edition
News about
Everest Medicines Acquires Greater China Rights to Cardamyst Nasal Spray in USD 50 Million Deal
Everest Medicines has entered into an asset purchase agreement with Corxel Pharmaceuticals Hong Kong Limited to acquire exclusive rights to develop, manufacture, and commercialize Cardamyst (etripamil) nasal spray across Greater China, including mainland China, Hong Kong, Macao, and Taiwan.
Viatris Secures Japan Approval for Effexor SR as First Treatment for Generalised Anxiety Disorder
Japan’s health ministry approves Effexor SR for adult GAD, marking the first and only authorised treatment in the country and expanding access to mental health care.
Insilico Medicine Launches PandaClaw AI Platform for Drug Discovery
Insilico Medicine launches PandaClaw AI platform to accelerate drug discovery, enabling real-time analysis, target identification and disease hypothesis generation through an intuitive natural language interface.
Japan’s health ministry approves the first in world combination of Lunsumio and Polivy, showing strong response rates and reduced disease progression risk in relapsed or refractory lymphoma patients.
Galderma Wins FDA Approval for Restylane Contour for Temple Hollowing
FDA approves Galderma’s Restylane Contour for temple hollowing, expanding its use with natural-looking results lasting up to 18 months and high patient satisfaction.
Bio-Thera Expands Partnership with Intas for BAT2506 Biosimilar in India
Bio-Thera has expanded its partnership with Intas Pharmaceuticals to commercialise BAT2506, a proposed golimumab biosimilar, in India.
CDR-Life Hits First Milestone in Boehringer Ingelheim Autoimmune Deal
CDR-Life has achieved its first milestone in its partnership with Boehringer Ingelheim, advancing an antibody-based programme targeting autoimmune diseases.
Gilead Sciences to Acquire Ouro Medicines in USD 2 Billion Deal to Strengthen Immunology Pipeline
Gilead Sciences has announced a definitive agreement to acquire Ouro Medicines in a deal valued at over USD 2 billion, marking a strategic move to expand its immunology and inflammation pipeline.
194 Drug Samples Fail Quality Tests, CDSCO Flags 4 as Spurious in February Review
Central Drugs Standard Control Organisation has identified 194 drug samples as “Not of Standard Quality” (NSQ) during its routine monthly surveillance for February 2026, while four additional samples have been flagged as spurious.
India Cracks Down on Misuse of GLP-1 Weight Loss Drugs Amid Semaglutide Surge
Central Drugs Standard Control Organisation has initiated a nationwide crackdown to curb potential malpractices in the pharmaceutical supply chain and prevent the unauthorized sale and misuse of GLP-1 receptor agonist-based weight loss drugs, following the rapid entry of multiple generic versions of semaglutide in India.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy